Development Reports and Information. Gen-Probe and Chiron each shall keep the other informed of the progress of such party under the Development Programs for Blood Screening Assays and Blood Screening Instruments. Within thirty (30) days following the end of each calendar quarter during the term of the Development Programs for Blood Screening Assays and Blood Screening Instruments, and within thirty (30) days following the expiration or termination of such Development Programs, Gen-Probe and Chiron each shall prepare and provide to the other party a reasonably detailed written summary report which shall describe the work performed by such party to date under such Development Programs. ***Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
Development Reports and Information. Gen-Probe and Chiron shall keep each other informed of their progress under the Development Programs for Clinical Diagnostic Assays and Clinical Diagnostic Instruments. The parties shall develop reasonable procedures for requesting and delivering copies of such records to each other as may be necessary for the performance of the Development Programs for Clinical Diagnostic Assays and Clinical Diagnostic Instruments. Within thirty (30) days following the end of each calendar quarter during the term of the Development Programs for Clinical Diagnostic Assays and Clinical Diagnostic Instruments, and within thirty (30) days following the expiration or termination of such Development Programs, Gen-Probe and Chiron each shall prepare and provide to the other party a reasonably detailed written summary report which shall describe the work performed by such party to date under such Development Programs.
Development Reports and Information. Gen-Probe and Novartis each shall keep the other informed of the progress of such party under the Development Programs for Blood Screening Assays and Blood Screening Instruments.
Development Reports and Information. Xxxxxxx-Xxxxx shall keep Ixsys informed as to the progress of the preclinical and clinical development and testing of all Products which Xxxxxxx-Xxxxx elects to develop and the preparing, filing and obtaining of the approvals necessary for marketing of all Products. Within thirty (30) days following each April 30, August 31 and December 31 following the commencement of preclinical development of a Product undertaken by Xxxxxxx-Xxxxx, Xxxxxxx-Xxxxx shall provide to Ixsys a written report which shall summarize the progress of the development and testing of Products in preclinical development and clinical trials. In addition, Xxxxxxx-Xxxxx shall provide to Ixsys a minimum of six (6) months advance written notice of the contemplated filing of an Investigational New Drug application ("IND") with the FDA in the United States (or its equivalent in any other country), a written report which shall summarize all other regulatory submissions prior to the date of such submissions, and written notice of all approvals obtained promptly after obtaining such approvals.
Development Reports and Information. From and after the Effective Date, within [**] following the end of each [**] prior to Completion of the Arvinas Clinical Trials Transfer, Arvinas shall provide to the JSC (or, Novartis, if the JSC has been disbanded) (x) a reasonably detailed written report of the Arvinas Clinical Trial Activities conducted during such [**], as applicable, which report shall contain sufficient detail to enable the JSC (or Novartis, if the JSC has been disbanded) to assess Arvinas’ compliance with the Arvinas Development Plan [**] and this Agreement; and (y) access to or copies of any final written reports related to such Arvinas Clinical Trial Activities (or results of analyses thereof) as may be prepared by or on behalf of Arvinas or its Affiliates. Upon the reasonable request of Novartis from time to time, Arvinas shall make appropriate personnel with knowledge of the Arvinas Clinical Trial Activities available to Novartis to discuss such activities and provide or make available to Novartis all Data arising from the Arvinas Clinical Trial Activities in its possession or Control and not previously provided or made available. (b)
Development Reports and Information. Following the expiration of the Research Program and during the Development Program, Bayer shall keep Immune Response informed as to the progress of the clinical development of each Product and the progress in preparing, filing and obtaining of the necessary marketing and pricing approvals to commercially sell and use the Product. Within thirty (30) days following the end of each June and December during the term of the Development Program, Bayer shall prepare, and provide to Immune Response, a summary written report which shall describe the progress of the clinical development and testing of Products in such clinical trials, the status of manufacturing such Product and the preparations to manufacture and supply such Product for any future clinical development and commercial sale, all regulatory filings and submissions made and all approvals obtained.
Development Reports and Information. Gen-Probe and Chiron each shall keep the other informed of the progress of such party under the Development Programs for Blood Screening Assays and Blood Screening Instruments. Within thirty (30) days following the end of each calendar quarter during the term of the Development Programs for Blood Screening Assays and Blood Screening Instruments, and within thirty (30) days following the expiration or termination of such Development Programs, Gen-Probe and Chiron each shall prepare and provide to the other party a reasonably detailed written summary report which shall describe the work performed by such party to date under such Development Programs.
